Saltar al contenido
Merck
Todas las fotos(1)

Documentos clave

C2174000

Cilazapril

European Pharmacopoeia (EP) Reference Standard

Sinónimos:

Cilazapril monohydrate

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización


About This Item

Fórmula empírica (notación de Hill):
C22H31N3O5 · H2O
Número de CAS:
Peso molecular:
435.51
Número MDL:
Código UNSPSC:
41116107
NACRES:
NA.24

grado

pharmaceutical primary standard

familia API

cilazapril

fabricante / nombre comercial

EDQM

aplicaciones

pharmaceutical (small molecule)

Formato

neat

temp. de almacenamiento

2-8°C

cadena SMILES

N21N(CCC[C@H]2C(=O)O)CCC[C@@H](C1=O)N[C@@H](CCc3ccccc3)C(=O)OCC.O

InChI

1S/C22H31N3O5.H2O/c1-2-30-22(29)18(13-12-16-8-4-3-5-9-16)23-17-10-6-14-24-15-7-11-19(21(27)28)25(24)20(17)26;/h3-5,8-9,17-19,23H,2,6-7,10-15H2,1H3,(H,27,28);1H2/t17-,18-,19-;/m0./s1

Clave InChI

JQRZBPFGBRIWSN-YOTVLOEGSA-N

Descripción general

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Aplicación

Cilazapril EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Envase

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Otras notas

Sales restrictions may apply.

Producto relacionado

Referencia del producto
Descripción
Precios

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documentos section.

Si necesita más asistencia, póngase en contacto con Atención al cliente

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

IgA nephropathy: a disease in search of a large-scale clinical trial to reliably inform practice.
Giovanni F M Strippoli et al.
American journal of kidney diseases : the official journal of the National Kidney Foundation, 53(1), 5-8 (2008-12-23)
High-dose angiotensin-converting enzyme inhibitor attenuates oxidative stress in patients with chronic kidney disease.
Marcin Renke et al.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 24(2), 689-690 (2008-12-05)
Leszek Tylicki et al.
Scandinavian journal of urology and nephrology, 42(4), 381-388 (2009-02-21)
Despite the proven effectiveness of combination therapy with an angiotensin I-converting enzyme inhibitor (ACEI) and angiotensin II-receptor blockers (ARBs) for the prevention and treatment of kidney disease, it has not proved possible to inhibit the progress of chronic nephropathies completely.
Mustafa Tuncer et al.
Advances in therapy, 25(2), 99-105 (2008-02-26)
P-wave dispersion (PWD) has been shown to be a non-invasive electrocardiographic predictor for development of atrial fibrillation (AF). Thus, it may be possible to decrease AF risk through improvement in PWD. Our objective was to compare the effects of cilazapril
Eduardo Cantoni Rosa et al.
Arquivos brasileiros de endocrinologia e metabologia, 52(1), 65-75 (2008-03-18)
Blood pressure (BP) and target organ responses to antihypertensive drugs are not well established in hypertensive obese patients. This study is aimed at evaluating the effects of obesity and adiposity distribution patterns on these responses. 49 hypertensive obese women were

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico